Why the study?
What are the pharmacokinetics and safety of intraperitoneal doxorubicin in patients with abdominopelvic malignancies?
What are the pharmacokinetics and safety of intraperitoneal doxorubicin in patients with abdominopelvic malignancies?
Intraperitoneal doxorubicin can be administered at moderate concentrations, but its usefulness is likely limited to patients with minimal abdominal disease due to local toxicity.
Answers are grounded in this paper and cite their sources.
Local toxicity likely restricts IP doxorubicin to minimal disease; leaves open its efficacy and safety in controlled trials.
Seventy intraperitoneal administrations of doxorubicin were performed in 12 patients with malignant disease in the abdominopelvic space. Peritoneal and hematologic drug levels were measured by fluorimetric assay. A first-order decline in the peritoneal level was determined (T 1/2 96 +/- 18 min), with a mean drug absorption of 84% in 4 h (range 40-96%) and a mean ratio of a peak dialysate/peak serum level of 111 (range 12-390). Gastrointestinal toxicity was common and peritoneal phlogosis occurred twice. The doxorubicin level and the time of peritoneal exposure seem to be critical factors for major local toxicity. At a moderate concentration doxorubicin can be intraperitoneally administered, but its usefulness is probably confined to patients with minimal abdominal disease.
No takes yet. Share an insight, caveat, or question.
Demicheli et al. (1985) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: